What Вальпроком 500 Хроно Treats: Main Uses and Benefits

Valprokom 500 Chrono is relevant in conditions characterized by episodic or fluctuating symptom patterns across several key domains, supporting the patient during difficult episodes by easing distress. The conditions for which the medication is commonly used include various types of epilepsy for seizure control, the management of acute manic episodes associated with bipolar disorder, and the prophylaxis of recurrent migraine headaches.

The medication is generally applied in clinical settings that involve acute or unstable symptom patterns, helping to ease the overall symptom burden. It assists with managing symptom clusters related to heightened neurological activity, such as convulsions, loss of consciousness, and extreme mood volatility.

“The purpose of this therapy is to provide supportive relief that helps patients cope more steadily with symptom fluctuations, focusing on symptomatic support rather than curative treatment.”

Quick Fact: Relief for Episodic Symptom Burden

Property	Description
Therapeutic Role	Seizure control, mood stabilization, migraine prevention
Symptom Type	Episodic, fluctuating, and acute manifestations
Therapeutic Benefit	Supports maintenance of functional stability
Context of Use	Chronic conditions requiring sustained symptomatic assistance
Primary Symptom Support	Easing the overall symptom load

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Вальпроком 500 Хроно?

Eligibility for Вальпроком 500 Хроно (Valproate) is strictly defined by government regulatory documents, focusing on patient age, metabolic function, and reproductive status.

Absolute Contraindications

Use of this medicine is strictly prohibited in populations with specific physiological conditions:

• Hepatic Disorders: Patients with active liver disease, severe hepatic dysfunction, or a history of drug-related severe liver failure.
• Metabolic Disorders: Individuals with known Urea Cycle Disorders (UCDs) or diagnosed mitochondrial disorders caused by the POLG gene (e.g., Alpers-Huttenlocher Syndrome).
• Hypersensitivity: Patients with known allergy to Valproate or any component of the formulation.

Age and Physiological Restrictions

Population Group	Regulatory Eligibility Statement
Women of Childbearing Potential	Contraindicated unless the conditions of a Pregnancy Prevention Programme (PPP) are met.
Pregnancy	Contraindicated for migraine prophylaxis; highly restricted for epilepsy, used only if no alternative exists.
Children under 2 years	Use requires extreme caution due to considerably higher risk of fatal hepatotoxicity.
Pediatric Patients	Safety and effectiveness are not established for epilepsy under 10 years of age or for migraine prophylaxis under 12 years of age.
Renal Impairment	Use requires caution, but is not an absolute contraindication.

These official statements define which populations are eligible to use the medicine and under what regulatory-mandated conditions.

The official regulatory profile for Valproic Acid/Sodium Valproate identifies several classes of documented interactions that affect plasma concentrations and clinical effects.

A severe pharmacokinetic restriction exists regarding Carbapenem antibiotics (such as Meropenem or Ertapenem). Co-administration with this class is strongly discouraged by regulatory authorities due to the risk of a rapid and significant reduction in Valproate concentrations, which can result in the loss of seizure control.

The clearance of Valproate itself is subject to bi-directional pharmacokinetic modulation. Drugs classified as hepatic enzyme inducers (e.g., Phenytoin, Carbamazepine, Rifampin) are documented to accelerate Valproate clearance, potentially lowering its exposure. Conversely, enzyme inhibitors (e.g., Felbamate) can decrease clearance, potentially raising concentrations.

Valproate is also documented to inhibit the metabolism of certain co-administered medicinal products, which can lead to increased plasma levels of other drugs, including Lamotrigine and Phenytoin.

A significant pharmacodynamic interaction is documented with Topiramate, co-administration of which is associated with an increased risk of hyperammonemia and encephalopathy. Additionally, the regulatory documents specify that the use of Valproate with alcohol or other CNS depressants carries an official risk of additive side effects such as increased drowsiness.

In specific populations, the interaction risk is heightened; for example, in children under two years of age on multiple anticonvulsant agents, the risk of toxicity is considerably higher. The label also contains administration sequence rules, such as initiating Valproate slowly in patients stabilized on Rufinamide.

Вальпроком 500 Хроно (valproate) exerts its effects through a multi-mechanistic action that modulates several key processes in the central nervous system.

---

Enhancement of Inhibitory Neurotransmission

This domain targets the neurotransmitter Gamma-aminobutyric acid (GABA), the brain's primary inhibitory signal. The drug increases GABA concentration by inhibiting the enzyme GABA transaminase (GABA-T), which is responsible for its catabolism. This pathway alters signal processing within neuronal circuits by attenuating excessive excitatory input.

---

Modulation of Neuronal Ion Channels

The drug acts by obstructing the rapid movement of ions essential for neuronal electrical signaling. It inhibits voltage-gated sodium channels, thereby reducing the high-frequency firing rate of neurons. It also inhibits specific T-type calcium channels, influencing rhythmic burst firing patterns. This combined channel effect results in reduced frequency of action potential generation.

---

Epigenetic Regulation of Gene Expression

Valproate is known to inhibit histone deacetylases (HDACs). By blocking these enzymes, the drug alters the structure of chromatin, which modifies the transcription and expression of various genes. This mechanism initiates signaling sequences that influence transcription factors and pathways associated with neuronal maintenance and plasticity.

The usage of Вальпроком 500 Хроно, a prolonged-release formulation of valproate, is defined by established administration principles. The approved route of administration is oral, with the tablet designed for once-daily dosing to ensure a sustained delivery of the active substance, though a divided schedule may be utilized for specific patient needs.

The therapy protocol requires controlled, incremental adjustment (titration). The initial dose for adults, such as 10 to 15 mg/kg/day for seizure control, is gradually increased over short intervals (e.g., 3 to 7 days) until the necessary maintenance dose is reached, typically in the 1,000 to 2,000 mg/day range. The maximum daily dose is subject to the specific indication, often capped at 2,500 mg in adult populations. Initiation and dose stabilization are generally conducted under the oversight of a specialist.

A critical procedural requirement is tablet integrity; the prolonged-release form must be swallowed whole and must not be crushed, chewed, or divided, as this action would disrupt the controlled-release mechanism. Administration is generally advised with or after food to help mitigate potential gastrointestinal irritation. Dosing rules also account for specific populations: older adults typically require a reduced starting dose and slower titration, and pediatric dosing is calculated based on body weight (mg/kg). If a dose is missed, it is advised to resume the regular schedule without doubling the subsequent dose.

Research evidence / Overview of studies for Вальпроком 500 Хроно

Overview of the Research Landscape

The evidence base for Вальпроком 500 Хроно (Valproate) is built on decades of research. This includes Randomized Controlled Trials (RCTs), where people are randomly assigned to receive the medication or a comparator (often a placebo or another active drug), and systematic reviews that combine findings from multiple high-quality trials. The long-term use of this medicine means evidence also includes extensive observational studies and post-marketing surveillance that monitor patterns in real-world clinical settings.

---

Evidence for Use in Epilepsy (Seizure Control)

Valproate was studied in research examining a variety of seizure types, including generalized tonic-clonic and absence seizures. Research generally focuses on studies conducted during periods of increased symptom activity related to seizure manifestations. The primary studies conducted were short-term and intermediate-term RCTs, and they examined outcomes related to systemic or functional imbalance, such as the frequency of seizures and the proportion of participants who became seizure-free over a defined time interval. Findings describe patterns observed in the studies regarding seizure frequency measurements in the observed populations.

Evidence for Use in Bipolar Disorder

The research for Вальпроком 500 Хроно in Bipolar Disorder is separated into two areas, focusing on studies of acute episode changes and long-term symptom patterns.

Acute Manic Episodes

Valproate was studied for its evaluation during conditions involving periods of heightened symptoms. Studies report how symptoms evolved in the observed populations during the study period, focusing on changes in symptom intensity or variability. While studies were conducted in adults when compared to placebo, and research exploring comparisons with other active mood-stabilizing medications reported mixed findings.

Long-Term Maintenance and Relapse Prevention

Valproate was evaluated in research exploring long-term symptom changes, focusing on conditions presenting with cycles of stability and flare-ups. Research highlights changes measured during the study period in functional stability metrics. However, comparative evidence against all contemporary long-term maintenance treatments is lacking, and long-term effects are not fully established.

---

Areas of Uncertainty and Research Gaps

Research provides insight into short-term changes and group patterns, but evidence highlights what is known—and what is still uncertain. Data for certain groups remain insufficient. For instance, dedicated high-quality evidence in children and adolescents is sparse for acute mania and limited for migraine prophylaxis. Furthermore, long-term effects are not fully established across all primary uses. The results apply only to the populations studied, meaning research provides context but not individual predictions.

Key Studies & References

1. Valproic Acid - StatPearls - NCBI Bookshelf (General Therapeutic Review)
2. Valproate – reproductive risks (UK Government Regulatory Guidance)

Common questions about Вальпроком 500 Хроно (FAQ)

Q: What is Вальпроком 500 Хроно prescribed for, besides the primary disease?

A: Regulatory documents indicate that valproate is prescribed for controlling epileptic seizures. Additionally, official uses include the prevention of migraine headaches in adults and the treatment of manic episodes associated with bipolar disorder.

Q: Is Вальпроком 500 Хроно considered a psychotropic drug?

A: Valproate is primarily classified as an antiepileptic medicine, meaning it is used to control seizures. However, because it is also officially used to stabilize mood in bipolar disorder (manic episodes), some regulatory bodies may include it within the broader category of psychotropic agents due to its effects on the central nervous system.

Q: Can Вальпроком 500 Хроно cause habituation or dependence?

A: Official drug information and authoritative sources generally do not classify valproate as a substance that causes addiction, physical dependence, or drug-seeking behavior.

Q: Is it true that Вальпроком 500 Хроно affects weight (gain or loss)?

A: Official documents describe that taking valproate can be associated with weight changes, which is considered a common side effect. In most reported cases, this involves weight gain.

Q: What are the most common side effects people notice in the first weeks of taking the medication?

A: The most common side effects reported at the start of treatment include gastrointestinal issues such as nausea, vomiting, and diarrhea. Central nervous system effects like drowsiness and tremor are also frequently noted. Some reports suggest that many initial symptoms may lessen with continued use, but this varies individually.

Q: Can I suddenly stop taking Вальпроком 500 Хроно if I feel better?

A: Regulatory warnings state that abrupt discontinuation of valproate could lead to the recurrence or worsening of the underlying condition, including an increase in the frequency of seizures. Official guidance indicates that discontinuation requires specialist supervision and a gradual reduction process.

Q: Are there restrictions on driving a car while taking this medication?

A: Official drug labels carry warnings about avoiding driving or operating heavy machinery until the individual's response to the medication's effects on concentration is established. This is due to the potential for side effects such as drowsiness, dizziness, or impaired cognition.

Q: Can Вальпроком 500 Хроно affect the menstrual cycle in women?

A: Official sources have reported that valproate use may be associated with menstrual cycle irregularities and, in some cases, the development of polycystic ovary syndrome (PCOS) in women.

Q: What should be done for severe nausea or stomach upset from Вальпроком 500 Хроно?

A: Gastrointestinal disturbances are common side effects, especially when starting treatment. Official guidelines suggest that taking the medication with or after food may help reduce these effects. If symptoms are persistent or severe, evaluation by a healthcare professional is necessary.

Q: Can the medication cause hair loss?

A: Yes, alopecia (hair loss) is a registered side effect associated with valproate. Regulatory documents mention that this effect has been reported as reversible in some cases.

Q: Does Вальпроком 500 Хроно interact with alcohol?

A: Official regulatory information advises that consuming alcohol while taking valproate may enhance central nervous system effects, such as drowsiness and dizziness. Due to the potential for enhanced sedative effects, official information advises caution regarding alcohol consumption.

Q: Can Вальпроком 500 Хроно be taken along with antidepressants?

A: Valproate can be prescribed together with antidepressants, but this requires monitoring. The combination may intensify some effects, such as sedation, or alter the blood concentration levels of the medications involved.

Q: Does Вальпроком 500 Хроно affect concentration and memory?

A: Valproate is associated with central nervous system side effects such as drowsiness, dizziness, and cognitive impairment. These effects are listed in official documents as potentially influencing attention span and memory function.

Q: Is it safe to take Вальпроком 500 Хроно during pregnancy?

A: Valproate is associated with a significant risk of causing birth defects and developmental disorders in children. Its use during pregnancy is associated with high risks and is subject to strict regulatory constraints, including contraindication for migraine prophylaxis. Regulatory frameworks often mandate participation in a specific pregnancy prevention program for female patients of childbearing potential.

Q: Are there studies on the long-term consequences of taking Вальпроком 500 Хроно?

A: Yes, long-term studies and follow-up observations describe potential distant effects. These include possible influences on metabolic function and the mineral density of bones (osteoporosis).

Q: How often do serious adverse reactions occur?

A: Serious adverse reactions, such as severe liver damage or pancreatitis, are described in official documents as rare but potentially fatal. Due to the potential severity of rare reactions, regulatory bodies emphasize the need for close monitoring for early symptoms, particularly within the first six months.

Q: Can Вальпроком 500 Хроно cause drowsiness or fatigue?

A: Drowsiness (sedation), fatigue (asthenia), and tremor are listed in official product information as very common side effects of valproate.

Q: What is 'withdrawal syndrome' when stopping Вальпроком 500 Хроно?

A: This term refers to the risk of relapse or worsening of the underlying symptoms, such as seizures, that may occur if the drug is stopped suddenly. Official product information emphasizes that discontinuation should be gradual and medically supervised to manage this risk.

Q: How does Вальпроком 500 Хроно affect the pancreas?

A: Valproate is associated with a risk of developing pancreatitis (inflammation of the pancreas), which can be severe and occasionally fatal. Regulatory warnings highlight this risk and state that immediate professional evaluation is necessary if symptoms associated with pancreatitis appear.

Q: What forms of Вальпроком 500 Хроно are available?

A: The specific product, Вальпроком 500 Хроно, is a prolonged-release tablet formulation. Valproate in general is available in various forms, including immediate-release tablets and syrups, depending on the specific brand and regulatory jurisdiction.

Q: In what cases is Вальпроком 500 Хроно contraindicated?

A: Contraindications listed in official documents include pre-existing liver disease or severe hepatic dysfunction, known disorders of the urea cycle, and hypersensitivity to the components. It is also contraindicated for migraine prophylaxis during pregnancy.

Q: Is there a risk of developing depression while taking Вальпроком 500 Хроно?

A: Regulatory authorities warn that antiepileptic drugs, including valproate, may be associated with a small increased risk of suicidal thoughts or behavior. Regulatory guidelines indicate that monitoring for changes, such as new or worsening depression or unusual mood changes, is part of the established safety protocol.

Q: What are the signs of an overdose of Вальпроком 500 Хроно?

A: Signs of overdose described in official product information typically include deep sleep (coma), central nervous system depression, muscle weakness, decreased reflexes, and potentially low blood pressure and heart rhythm disturbances.

Q: Does the dose of Вальпроком 500 Хроно need to be adjusted for kidney diseases?

A: Official information indicates that while valproate is primarily metabolized by the liver, dose adjustments may be necessary in cases of kidney impairment. Specialist supervision is required when considering use in individuals with kidney impairment.

Q: Does the drug affect the effectiveness of oral contraceptives?

A: Valproate is generally not considered to significantly reduce the effectiveness of most hormonal contraceptives. However, due to the high fetal risks associated with valproate, official safety measures include recommendations for effective contraception.

Q: What should be done if a rash appears while taking Вальпроком 500 Хроно?

A: The appearance of a rash can be a sign of a severe hypersensitivity reaction. The appearance of any new skin reaction mandates immediate professional evaluation as per regulatory safety instructions.

Q: Can Вальпроком 500 Хроно affect blood formation?

A: Valproate can cause changes in blood tests, including a decrease in the number of platelets (thrombocytopenia) and other blood cell abnormalities. For this reason, official safety protocols involve regular blood analysis.

Q: Is there a risk of developing pancreatitis from Вальпроком 500 Хроно?

A: Yes, the risk of developing pancreatitis (inflammation of the pancreas) is a key safety warning from regulatory bodies, as it can be severe and life-threatening. This risk is why regulatory authorities recommend careful monitoring for associated symptoms.

Q: Why are regular blood tests needed when taking Вальпроком 500 Хроно?

A: Analysis of blood is required to monitor vital organ functions, specifically the liver and pancreas, and to check blood cell counts and the concentration of valproate in the blood. This process is essential for detecting and preventing potential serious side effects, particularly during the early stages of therapy.

Q: What does the prefix 'Chrono' in the drug name mean?

A: The term 'Chrono' indicates that the formulation is a prolonged-release or extended-release type. This means the active substance (valproate) is released slowly over time to ensure a stable and long-lasting effect throughout the day, often allowing for once-daily dosing.

Q: What is the 'therapeutic concentration' of Вальпроком 500 Хроно in the blood?

A: Therapeutic concentration refers to the specific range of valproate levels in the bloodstream. According to scientific data, levels within this range are most likely associated with achieving the desired therapeutic effect (disease control) while minimizing the risk of adverse side effects.

Q: If I have bipolar disorder, why am I prescribed Вальпроком 500 Хроно?

A: Valproate sodium is officially indicated and used for the treatment of manic episodes associated with bipolar disorder, a condition characterized by significant mood disturbances. It is also used to help prevent the recurrence of these episodes.

Q: Why is Вальпроком 500 Хроно prescribed for migraine treatment?

A: Valproate is officially indicated for the prophylactic (preventive) treatment of migraine headaches in adults. This is typically prescribed when other types of treatment have been unsuitable or ineffective.

Q: How long does it take to see the effect after starting Вальпроком 500 Хроно?

A: It may take several weeks to observe the full therapeutic effect. This time is often necessary to gradually increase the dosage (titration) and to allow the drug to reach a steady, effective concentration in the bloodstream.

Q: How soon after starting Вальпроком 500 Хроно does it start working?

A: The active substance begins to be absorbed into the bloodstream shortly after taking the prolonged-release tablet. However, achieving the required stable and effective concentration (therapeutic level) often takes several days to weeks of consistent dosing.

Q: If the medication is not helping, how long should one wait before changing treatment?

A: Evaluating the effectiveness of valproate requires a period of assessment after a stable blood concentration is achieved. The final decision to change treatment is made by a specialist after an observation period, which typically lasts several weeks.

Q: Is Вальпроком 500 Хроно compatible with taking vitamins or dietary supplements?

A: Some vitamins or supplements may potentially affect the concentration or action of valproate. Official sources mention possible interactions with certain herbal products. It is important to report the use of all supplements or non-prescription products to the treating specialist.

Q: Can I operate heavy machinery while taking Вальпроком 500 Хроно?

A: Official documents contain warnings regarding the operation of heavy machinery or engaging in potentially hazardous activities until the effect of the medication on mental and motor skills is fully established. This is due to the risk of side effects like sedation or dizziness.

Q: How does Вальпроком 500 Хроно affect the liver?

A: Valproate can rarely cause severe, potentially fatal liver injury (hepatotoxicity). Due to this risk, regular monitoring of liver function is an established part of the official safety protocol, particularly during the first six months of therapy.

How to Store and Dispose of Вальпроком 500 Хроно

The storage and disposal of Вальпроком 500 Хроно (Valproate prolonged-release tablets) must strictly follow the conditions mandated by official regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 30 C
Container Protection	Must be kept in the original package to ensure protection from moisture and light
Child Safety	Must be stored out of the sight and reach of children

Storage outside of the prescribed temperature range or failure to protect the tablets from moisture and light may compromise product stability. The medicine must not be used after the expiration date printed on the packaging.

Disposal Instructions

Unused or expired Вальпроком 500 Хроно must be disposed of properly. This requires following local regulations and taking the medication to an authorized special waste collection point. The product must not be disposed of in household waste or wastewater.